Atrial Fibrillation Market by Product (Access Devices, Cardiac Monitors or Implantable Loop Recorder, EP Ablation Catheters), Device (Non-Surgical Devices, Surgical Devices), End-User - Global Forecast 2024-2030
The Atrial Fibrillation Market size was estimated at USD 9.46 billion in 2023 and expected to reach USD 10.75 billion in 2024, at a CAGR 13.71% to reach USD 23.28 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Atrial Fibrillation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Atrial Fibrillation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Atrial Fibrillation Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acesion Pharma ApS, AFreeze GmbH, AtriCure, Inc., AuriGen Medical, BIOTRONIK SE & CO. KG, Carima, Inc., CathRx Ltd, GE Healthcare, Japan Lifeline Co, Johnson & Johnson Services, Inc., Koninklijke Philips N.V, Medtronic PLC, Osypka AG, Siemens Healthcare GmbH, St. Jude Medical, Inc., and Vanguard AG.
Market Segmentation & Coverage
This research report categorizes the Atrial Fibrillation Market to forecast the revenues and analyze trends in each of the following sub-markets:
Product
Access Devices
Cardiac Monitors or Implantable Loop Recorder
EP Ablation Catheters
EP Diagnostic Catheter
Intracardiac Echocardiography
Left Atrial Appendage Closure Devices
Mapping & Recording Systems
Device
Non-Surgical Devices
Access Devices
Advanced Diagnostic Catheters
Cardiac Monitors
Conventional Diagnostic Catheters
Fixed Diagnostic Catheters
Steerable Diagnostic Catheters
Diagnostic Catheters
Electric Cardioversion
Intracardiac Echocardiography (ICE) Systems
Left Atrial Appendage & Closure Devices
Mapping & Recording Systems
Surgical Devices
Catheter Ablation
Cryoablation
Laser-Based Catheter Ablation
Maze Surgery
Microwave-Based Catheter Ablation
Navigational Advanced Mapping Accessories
Radiofrequency Catheter Ablation
Conventional RF Ablation Catheters
Irrigated-tip RF Ablation Catheters
End-User
Cardiology
Musculoskeletal
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom The report offers valuable insights on the following aspects:
Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
What is the market size and forecast of the Atrial Fibrillation Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Atrial Fibrillation Market?
What are the technology trends and regulatory frameworks in the Atrial Fibrillation Market?
What is the market share of the leading vendors in the Atrial Fibrillation Market?
Which modes and strategic moves are suitable for entering the Atrial Fibrillation Market?
Note: PDF & Excel + Online Access - 1 Year
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Atrial Fibrillation Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of atrial fibrillation in geriatric population
5.1.1.2. Government and global health organizations’ strategies to improve atrial fibrillation treatment
5.1.1.3. Increasing preference of catheter ablation for cardiac arrhythmia treatment
5.1.2. Restraints
5.1.2.1. High price of treatment and dearth of skilled professionals
5.1.3. Opportunities
5.1.3.1. Technology advancements in treatment and diagnostic methods to atrial fibrillation
5.1.3.2. Favorable approvals for atrial fibrillation drugs and treatment
5.1.4. Challenges
5.1.4.1. Incomplete understanding of the pathophysiology of AF
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Atrial Fibrillation Market, by Product
6.1. Introduction
6.2. Access Devices
6.3. Cardiac Monitors or Implantable Loop Recorder
6.4. EP Ablation Catheters
6.5. EP Diagnostic Catheter
6.6. Intracardiac Echocardiography
6.7. Left Atrial Appendage Closure Devices
6.8. Mapping & Recording Systems
7. Atrial Fibrillation Market, by Device
7.1. Introduction
7.2. Non-Surgical Devices
7.3.1. Access Devices
7.3.2. Advanced Diagnostic Catheters
7.3.3. Cardiac Monitors
7.3.4. Conventional Diagnostic Catheters
7.3.5.1. Fixed Diagnostic Catheters
7.3.5.2. Steerable Diagnostic Catheters
7.3.5. Diagnostic Catheters
7.3.6. Electric Cardioversion
7.3.7. Intracardiac Echocardiography (ICE) Systems
7.3.8. Left Atrial Appendage & Closure Devices
7.3.9. Mapping & Recording Systems
7.3. Surgical Devices
7.4.1. Catheter Ablation
7.4.2. Cryoablation
7.4.3. Laser-Based Catheter Ablation
7.4.4. Maze Surgery
7.4.5. Microwave-Based Catheter Ablation
7.4.6. Navigational Advanced Mapping Accessories
7.4.7. Radiofrequency Catheter Ablation
7.4.8.1. Conventional RF Ablation Catheters
7.4.8.2. Irrigated-tip RF Ablation Catheters
8. Atrial Fibrillation Market, by End-User
8.1. Introduction
8.2. Cardiology
8.3. Musculoskeletal
9. Americas Atrial Fibrillation Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Atrial Fibrillation Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Atrial Fibrillation Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Acesion Pharma ApS
13.1.3. AFreeze GmbH
13.1.4. AtriCure, Inc.
13.1.5. AuriGen Medical
13.1.6. BIOTRONIK SE & CO. KG
13.1.7. Carima, Inc.
13.1.8. CathRx Ltd
13.1.9. GE Healthcare
13.1.10. Japan Lifeline Co
13.1.11. Johnson & Johnson Services, Inc.
13.1.12. Koninklijke Philips N.V
13.1.13. Medtronic PLC
13.1.14. Osypka AG
13.1.15. Siemens Healthcare GmbH
13.1.16. St. Jude Medical, Inc.
13.1.17. Vanguard AG
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. ATRIAL FIBRILLATION MARKET RESEARCH PROCESS
FIGURE 2. ATRIAL FIBRILLATION MARKET SIZE, 2023 VS 2030